FRANKLYN G PRENDERGAST
CIK 1233256 · last filed 2023-10-04
FRANKLYN G PRENDERGAST is a corporate insider who has filed 27 SEC Form 4 insider transactions across 5 companies since 2007. The most recent filing, for IMNM, was dated Oct 4, 2023. Current disclosed insider exposure totals $78.8M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$78.81M
5
27
$0
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| IMNM | Director | 60,840 | $18.38 | $1.12M | $0 | 4 | 2023-10-04 |
| NeuBase Therapeutics, Inc. (NBSE) Delisted | Director | — | $0.38 | — | $0 | 4 | 2022-09-12 |
| LTRN | Director | — | $3.88 | — | $0 | 2 | 2021-11-08 |
| Vyant Bio, Inc. (CGIX) Delisted | Director | 12,500 | $4.61 | $57.6K | $0 | 6 | 2019-08-21 |
| LLY | Director | 68,574 | $1133.00 | $77.69M | $0 | 11 | 2017-11-22 |
Recent Filings
27 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-10-04 | IMNM | Grant (A) | +60,840 | $0 | EDGAR |
| 2023-06-12 | IMNM | Grant (A) | — | $0 | EDGAR |
| 2022-09-12 | NeuBase Therapeutics, Inc. (NBSE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-06-21 | IMNM | Grant (A) | — | $0 | EDGAR |
| 2021-11-08 | LTRN | Grant (A) | — | $0 | EDGAR |
| 2021-09-17 | NeuBase Therapeutics, Inc. (NBSE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-06-21 | IMNM | Grant (A) | — | $0 | EDGAR |
| 2020-09-11 | NeuBase Therapeutics, Inc. (NBSE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-06-15 | LTRN | Grant (A) | — | $0 | EDGAR |
| 2019-08-21 | Vyant Bio, Inc. (CGIX) Delisted | Grant (A) | — | $0 | EDGAR |